Bristol-Myers Squibb Company announced that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation.
Shares of PDL BioPharma Inc. plunged on word of a royalty dispute between PDL and its collaborator Genentech.
Federal health officials have approved a new type of morning-after contraceptive that works longer than the current leading drug on the market.
AMRI announced that it has been selected as the inaugural winner of the Pfizer Route Design Innovation Award, beating out 40 companies who were invited to share innovative ideas for process chemistry and large scale active pharmaceutical ingredient production.
BioClinica, Inc., a global provider of clinical trial management services, announced it has created strategic partnerships with two privately held clinical research organizations, Axio Research Corporation and Beardsworth Consulting Group, Inc.
Ricerca Biosciences, LLC, a preclinical contract research organization providing services to the biopharmaceutical industry, is pleased to announce the addition of Carlos Martínez Manchado to its Analytical Chemistry department.
Quay Pharma has been appointed by a leading Japanese pharmaceutical company to handle the clinical trial drug manufacture of two NCEs for UK trials. The contract was won in conjunction with Quay’s Japanese representative InterPharm Express.
Worldwide Clinical Trials, Inc., a privately held global contract research organization, announced that Evelyn Graham has joined the company as Executive Vice President, Global Business Development.
Concentration-gradient dynamic light scattering simplifies protein-protein interaction characterization.
When it comes to searching for specific proteins in a biological extract, many researchers still turn to the Western blot. Even after thirty years, this technique continues to be improved.
In addition to my duties on Drug Discovery & Development, I serve as Editorial Director of R&D Magazine. The readers of this publication are scientists and researchers also, but they develop a diverse range of technologies.
Pharma companies migrate to high-content screening approaches to screen for kinase inhibitors.
Data standards are routinely discussed within the life sciences industries today, and many research companies have been piloting the use of CDISC standards within their organization.
Every drug discovery organization seeks to improve the speed and success of its research efforts. But advances in the field—including high throughput screening, in silico modeling, biotherapeutics, and more—present a double-edged sword.